液滴数字PCR检测BRAFV600突变循环肿瘤DNA作为已切除III期黑色素瘤辅助治疗患者预后生物标志物的临床验证(COMBI-AD):一项双盲随机3期试验的生物标志物分析
COMBI-AD试验生物标志物分析,用经验证的液滴数字PCR检测597例已切除III期黑色素瘤患者基线血浆BRAFV600突变循环肿瘤DNA(ctDNA),发现ctDNA阳性与更差的无复发性生存和总生存相关,且优于肿瘤突变负荷和IFNG基因表达。纵向ctDNA动力学可识别高复发风险患者。
要点
- 基线ctDNA可检测于13%(79/597)的已切除III期黑色素瘤患者。
- ctDNA阳性与安慰剂组和联合治疗组更差的无复发性生存和总生存相关。
- 不良纵向ctDNA动力学(分子复发或持续阳性)者无复发性生存显著更短。
核心结论
- 辅助靶向治疗前及随访中检测ctDNA评估微小残留病可识别早期复发高危患者。
- 作者认为,使用ctDNA检测指导治疗干预的进一步研究可能改善已切除III期黑色素瘤的管理。
研究设计与样本
- COMBI-AD试验为双盲随机3期研究,比较口服达拉非尼(150 mg每日两次)联合口服曲美替尼(2 mg每日一次)与两种匹配安慰剂。
- 患者为18岁及以上、已切除BRAFV600突变III期黑色素瘤、ECOG体能状态0或1,2013年1月31日至2014年12月11日筛选入组,按1:1随机分配。
- 生物标志物分析为预设探索性终点,在意向治疗人群中进行,基线血浆样本来自870例中的597例(331例男性,266例女性)。
- 随访3、6、9、12个月时点ctDNA阳性率样本来自870例中的94例;临床或影像学复发前后2个月内样本来自870例中的118例。
- 联合治疗组生物标志物分析中位随访60个月(IQR 39-66),安慰剂组58个月(21-66)。
主要发现
- 597例基线样本中79例(13%)可检测到ctDNA;疾病亚分期越高,ctDNA阳性率和每mL血浆突变拷贝数显著更高。
- 安慰剂组:ctDNA阳性者中位无复发性生存3.71个月(95%CI 2.39-6.89) vs 阴性者24.41个月(17.28-43.13),HR 2.91(95%CI 1.99-4.25),p<0.0001。
- 联合治疗组:ctDNA阳性者中位无复发性生存16.59个月(95%CI 12.02-26.80) vs 阴性者68.11个月(50.36-未达到),HR 2.98(95%CI 1.95-4.54),p<0.0001。
- 安慰剂组:ctDNA阳性者中位总生存33.90个月(95%CI 13.96-未达到) vs 阴性者未达到,HR 3.35(95%CI 2.01-5.55),p<0.0001;联合治疗组:阳性者40.31个月(24.90-未达到) vs 阴性者未达到,HR 4.27(95%CI 2.50-7.27),p<0.0001。
- 不良纵向ctDNA动力学者中位无复发性生存:分子复发8.31个月(95%CI 5.39-12.20),持续阳性5.32个月(2.79-未达到);良好动力学者:基线阳性后转阴19.25个月(16.39-未达到),持续阴性未达到(38.44-未达到),p<0.0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cell-free, circulating tumour DNA (ctDNA) is an established measure of minimal residual disease; however, it is not utilised in melanoma management. We investigated whether ctDNA measurements could predict survival outcomes during adjuvant targeted therapy or placebo treatment in stage III melanoma, thereby identifying patients at high risk and low risk of recurrence. METHODS: Analytically validated mutation-specific droplet digital PCR assays were used to measure BRAFV600E or BRAFV600K ctDNA in patients aged 18 years or older who were enrolled in the COMBI-AD trial, which was a double-blind, randomised, phase 3 study of oral dabrafenib (150 mg twice daily) plus oral trametinib (2 mg once daily) combination therapy versus two matched placebos in resected BRAFV600-mutant stage III melanoma. Patients were screened for enrolment between Jan 31, 2013, and Dec 11, 2014, had an Eastern Cooperative Oncology Group performance status of 0 or 1, and were randomly assigned (1:1) to the two treatment groups. The primary endpoint was recurrence-free survival, and the results from final analysis have been previously published and will not be described here. Biomarker analysis was a prespecified exploratory endpoint and performed in the intention-to-treat population. We compared associations between survival outcomes and baseline (post-resection) ctDNA copies per mL, tumour mutational burden and interferon gamma (IFNG) gene expression. In a subset of patients, ctDNA quantities during follow-up or at recurrence were measured. The trial is registered with ClinicalTrials.gov, NCT01682083, and has been completed. FINDINGS: Baseline plasma samples were available for 597 of 870 patients (331 male patients and 266 female patients) and samples for assessing the ctDNA positivity rate at landmark follow-up timepoints of 3 months, 6 months, 9 months, and 12 months after treatment initiation were available for 94 of 870 patients. Additionally, samples were available from 118 of 870 patients within a 2-month timeframe before or after clinical or radiographic recurrence. Median follow-up for the biomarker analyses was 60 months (IQR 39-66) in the combination therapy group and 58 months (21-66) for the placebo group. ctDNA was detectable in 79 (13%) of 597 baseline samples. ctDNA positivity rate and mutant copies per mL plasma were significantly higher in patients with higher disease substages. As a binary variable, ctDNA detection was associated with worse recurrence-free survival (placebo group: median 3·71 months [95% CI 2·39-6·89] vs 24·41 months [17·28-43·13]; hazard ratio [HR] 2·91 [95% CI 1·99-4·25], p<0·0001); combination therapy group: median 16·59 months [95% CI 12·02-26·80] vs 68·11 months [50·36-not reached]; HR 2·98 [1·95-4·54], p<0·0001) and overall survival (placebo group: median 33·90 months [13·96-not reached] vs not reached; HR 3·35 [2·01-5·55], p<0·0001); combination therapy group: median 40·31 months [24·90-not reached] vs not reached; HR 4·27 [2·50-7·27], p<0·0001) in the placebo group and combination therapy groups. Baseline ctDNA was more strongly associated with survival outcomes than IFNG gene expression or tumour mutational burden. Patients with adverse longitudinal ctDNA kinetics (molecular relapse or persistently positive) had markedly shorter median recurrence-free survival (8·31 months [95% CI 5·39-12·20] and 5·32 months [2·79-not reached], respectively) compared with patients with favourable kinetics (ie, undetectable after positive baseline result: 19·25 months [16·39-not reached]; and durable undetectable: not reached [38·44-not reached], p<0·0001). INTERPRETATION: Droplet digital PCR measurements of ctDNA to assess minimal residual disease before adjuvant targeted therapy and during follow-up can identify patients at high risk of early recurrence. Additional studies using ctDNA measurements to guide therapeutic interventions might lead to improvements in the management of resected stage III melanoma. FUNDING: Novartis.
引用
- Syeda MM, Long GV, Garrett J, et al. Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial. Lancet Oncol. 2025. PMID: 40250457. doi:10.1016/S1470-2045(25)00139-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。